Clinical trials: Pegfilgrastim
Breast Cancer
Combination Chemotherapy in Treating Patients With Early Stage Breast Cancer That Has Been Removed By Surgery
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- TACT2 (NCT00301925)
- Testing
- pegfilgrastim, capecitabine, cyclophosphamide
- Where
- 152 sites in United Kingdom
- Volunteers
- 4,400 people
- Sponsor
- Institute of Cancer Research, United Kingdom
Multiple Myeloma, Lymphoma
Lapelga vs Gastrofil
This study is examining one-time injection of biosimilar pegfilgrastim compared with multiple injection biosimilar filgrastim post autologous hematopoietic stem cell transplantation.
- Conditions
- Multiple Myeloma, Lymphoma, Engagement, Patient, Febrile Neutropenia
- Trial name
- NCT06116734
- Testing
- Grastofil®, Lapelga
- Volunteers
- 74 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Pharmacokinetics
A Comparative, Crossover, Pharmacokinetic, Pharmacodynamic and Safety Study of Three Forms of PEG-G-CSF in Normal Healthy Volunteers
This is a comparative pharmacokinetic, pharmacodynamic and safety study in healthy volunteers with three forms of pegylated granulocyte colony stimulating factors.
- Trial name
- NCT02205320
- Testing
- DRL_PG, Pegfilgrastim Form A, Pegfilgrastim Form B
- Where
- United States
- Volunteers
- 192 people, healthy volunteers welcome
- Sponsor
- Dr. Reddy's Laboratories Limited
Healthy
Pharmacokinetic/Pharmacodynamic (PK/PD) Study Evaluating Pegfilgrastim Hospira Compared to Neulasta (Amgen) in Healthy Volunteers
This study compared the pharmacokinetics, pharmacodynamics and the safety of Pegfilgrastim Hospira and Neulasta® following a single dose of 6 mg of each product administered subcutaneously in Treatment Periods 1 and 2…
- Trial name
- NCT00938678
- Testing
- Pegfilgrastim Hospira, Neulasta (Amgen)
- Where
- United Kingdom
- Volunteers
- 71 people, healthy volunteers welcome
- Sponsor
- Hospira, now a wholly owned subsidiary of Pfizer
Breast Cancer
Six vs 12 Months of Trastuzumab With Docetaxel Following FEC as Adjuvant Treatment in N+ Breast Cancer
This trial will compare 6 versus 12 months of trastuzumab in combination with dose dense docetaxel following FE75C as adjuvant chemotherapy in women with axillary lymph node positive breast cancer overexpressing HER2
- Trial name
- NCT00615602
- Testing
- Docetaxel, Trastuzumab, Epirubicin
- Where
- 10 sites in Greece
- Volunteers
- 489 people
- Sponsor
- Hellenic Oncology Research Group
Non-Hodgkin's Lymphoma
IIT CTI Bendamustine, Rituximab, Pixantrone in Relapsed/Refractory B Cell Non-Hodgkin's Lymphoma
This is a phase I trial of the combination of bendamustine, rituximab and pixantrone in patients with relapsed/refractory B cell non-Hodgkin lymphoma.
- Trial name
- BRP (NCT01491841)
- Testing
- Bendamustine + Rituximab + Pixantrone, Pegfilgrastim
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Anne Beaven, MD
Breast Cancer, Metastatic Breast Cancer
Phase 2 Neoadjuvant Doxorubicin and Cyclophosphamide -> Docetaxel With Lapatinib in Stage II/III Her2Neu+ Breast Cancer
This trial combines dose dense chemotherapy with doxorubicin and cyclophosphamide (AC) followed by standard, every 3 week docetaxel and GW572016 (lapatinib) for neoadjuvant treatment of Her2neu positive stage II/III breast…
- Trial name
- NCT00404066
- Testing
- Lapatinib, Doxorubicin, Cyclophosphamide
- Where
- 2 sites in United States
- Volunteers
- 21 people
- Sponsor
- George Albert Fisher
Fallopian Tube Cancer, Ovarian Cancer
Erlotinib, Docetaxel, and Carboplatin in Treating Patients With Newly Diagnosed Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer
RATIONALE: Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as docetaxel and carboplatin, work in different ways to stop the growth of tumor…
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer
- Trial name
- NCT00217529
- Testing
- pegfilgrastim, carboplatin, docetaxel
- Where
- 3 sites in United States
- Sponsor
- Fred Hutchinson Cancer Center
Breast Cancer
PEG-rhG-CSF in Patients With Breast Cancer Receiving Chemotherapy
The purpose of this study is to evaluate the efficacy and safety of PEG-rhG-CSF in patients with breast cancer receiving chemotherapy
- Trial name
- NCT02805153
- Testing
- PEG-rhG-CSF, rhG-CSF
- Volunteers
- 215 people
- Sponsor
- CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
Multiple Myeloma
Pegfilgrastim (Neulasta) for Stem Cell Mobilization in Patients With Multiple Myeloma
In recent years PBPC have replaced bone marrow as the source of hematopoietic stem cells for autologous transplantation. One of the cited advantages of this procedure is the avoidance of bone marrow harvest, which frequently…
- Trial name
- NCT00067639
- Testing
- Pegfilgrastim (Neulasta), Apheresis
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- M.D. Anderson Cancer Center
Multiple Myeloma
Study of Plinabulin and Pegfilgrastim in People With Multiple Myeloma Undergoing an Autologous Hematopoietic Stem Cell Transplant (AHCT)
This study will see how long it takes for white blood cell counts to return to normal in people with multiple myeloma (MM) who receive plinabulin and pegfilgrastim after undergoing an autologous hematopoietic stem cell transplant…
- Trial name
- NCT05130827
- Testing
- Plinabulin
- Where
- 7 sites in United States
- Volunteers
- 17 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Lymphoma
Diffuse Large B Cell Non-Hodgkin's Lymphoma in the Vulnerable/Frail Elderly. A Multicentric Randomized Phase II Trial
RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread.
- Trial name
- FRAIL-06 (NCT00911183)
- Testing
- filgrastim, pegfilgrastim, rituximab
- Where
- France
- Volunteers
- 67 people
- Sponsor
- Institut Bergonié
Leukemia
CLL-Irl Study. CTRIAL-IE (ICORG) 07-01, V7
RATIONALE: Drugs used in chemotherapy, such as fludarabine and cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00812669
- Testing
- pegfilgrastim, rituximab, cyclophosphamide
- Where
- 7 sites in Ireland
- Volunteers
- 52 people
- Sponsor
- Cancer Trials Ireland
Recurrent Uterine Corpus Sarcoma, Uterine Corpus Leiomyosarcoma
Combination Chemotherapy and Filgrastim or Pegfilgrastim in Treating Patients With Recurrent or Persistent Cancer of the Uterus
Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00031629
- Testing
- Docetaxel, Filgrastim, Gemcitabine Hydrochloride
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- Gynecologic Oncology Group
Lymphoproliferative Disorder, HHV-8
Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity
This study will gain information about a rare disorder called KSHV-associated multicentric Castleman's disease (MCD). KSHV, a virus, causes several kinds of cancer, including some forms of MCD.
- Conditions
- Lymphoproliferative Disorder, HHV-8, Malignancy, HIV
- Trial name
- NCT00092222
- Testing
- Etoposide, Interferon-alpha, Rituximab
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- National Cancer Institute (NCI)
Neutropenia
A Real World Study Evaluating the Clinical Application of PEG-rhG-CSF During Chemotherapy in Patients With Solid Tumors
Prospective, multicenter, non-interventional registration studies were used in this project . Eight hundreds patients with solid tumors who met the inclusion criteria in six hospitals in Sichuan Province, Sichuan Province, were…
- Trial name
- NCT03798665
- Testing
- Pegfilgrastim（PEG-rhG-CSF）
- Where
- China
- Volunteers
- 800 people
- Sponsor
- Affiliated Hospital of North Sichuan Medical College
Diabetes Mellitus, Type 1
ATG-GCSF in New Onset Type 1 Diabetes
This is a three-arm, 1:1:1 randomized, placebo controlled, double- blinded trial in which at least 28 subjects will receive active Anti-Thymocyte Globulin and Granulocyte colony-stimulating factor (ATG-GCSF), at least 28 subjects…
- Trial name
- ATG-GCSF (NCT02215200)
- Testing
- Anti-Thymocyte Globulin (ATG), Granulocyte colony stimulating factor (GCSF)
- Where
- 13 sites in United States
- Volunteers
- 89 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Chronic Lymphocytic Leukemia (CLL)
Clinical Protocol for the Treatment of Patients With Previously Untreated Chronic Lymphocytic Leukemia With a Combination of Bendamustine and Ofatumumab
Investigational Drug: Ofatumumab (Azerra) Route of Administration: Intravenous (IV) Hypothesis: This study is designed to assess the toxicity and overall response rate.
- Trial name
- NCT01125787
- Testing
- ofatumumab + bendamustine
- Where
- 2 sites in United States
- Volunteers
- 1 people
- Sponsor
- Nevada Cancer Institute
Healthy
Study to Assess the Pharmacokinetic and Pharmacodynamic Bioequivalence of CHS-1701 With Neulasta
This is a randomized, single-blind, 3-period crossover study in healthy subjects to assess PK, PD, and safety (including immunogenicity) of a single 6mg subcutaneous injection of CHS-1701 (Coherus pegfligrastim) or 6mg SC dose of…
- Trial name
- NCT02650973
- Testing
- CHS-1701, Pegfilgrastim
- Where
- 4 sites in United States
- Volunteers
- 122 people, healthy volunteers welcome
- Sponsor
- Coherus Oncology, Inc.
Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral
Phase I Study of Romidepsin, Gemcitabine, Oxaliplatin, and Dexamethasone in Patients With Relapsed/Refractory Aggressive Lymphomas
The purpose of this research study is to find the maximum tolerated dose of a drug called romidepsin when given with a treatment regimen called GemOxD.
- Conditions
- Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Hodgkin Disease, Lymphoma, Large B-Cell, Diffuse
- Trial name
- NCT02181218
- Testing
- Romidepsin, Gemcitabine, Oxaliplatin
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- Washington University School of Medicine